Format
Sort by

Send to

Choose Destination

Search results

Items: 11

1.

The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.

Smolen LJ, Gahn JC, Mitri G, Shiozawa A.

Clin Ther. 2016 Jul;38(7):1710-25. doi: 10.1016/j.clinthera.2016.05.007. Epub 2016 Jun 3.

PMID:
27269247
2.

Febuxostat in the management of gout: a cost-effectiveness analysis.

Smolen LJ, Gahn JC, Mitri G, Shiozawa A.

J Med Econ. 2016;19(3):265-76. doi: 10.3111/13696998.2015.1116990. Epub 2015 Nov 23.

PMID:
26535593
3.

Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting.

Eby EL, Smolen LJ, Pitts AC, Krueger LA, Andrews JS.

Consult Pharm. 2014 Dec;29(12):813-22. doi: 10.4140/TCP.n.2014.813.

PMID:
25521657
4.

Outcomes in Severe Osteoporotic Women in Korea Using Sequential Treatment.

Kim BR, Burge R, Klein TM, Smolen LJ.

Value Health. 2014 Nov;17(7):A771. doi: 10.1016/j.jval.2014.08.317. Epub 2014 Oct 26. No abstract available.

5.

Using common random numbers in health care cost-effectiveness simulation modeling.

Murphy DR, Klein RW, Smolen LJ, Klein TM, Roberts SD.

Health Serv Res. 2013 Aug;48(4):1508-25. doi: 10.1111/1475-6773.12044. Epub 2013 Feb 13.

6.

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.

Murphy DR, Smolen LJ, Klein TM, Klein RW.

BMC Musculoskelet Disord. 2012 Oct 30;13:213. doi: 10.1186/1471-2474-13-213.

7.

Budget impact analysis of insulin therapies and associated delivery systems.

Lee LJ, Smolen LJ, Klein TM, Foster SA, Whiteman D, Jorgenson JA, Hultgren S.

Am J Health Syst Pharm. 2012 Jun 1;69(11):958-65. doi: 10.2146/ajhp110333.

PMID:
22610028
8.

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.

Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD.

J Med Econ. 2012;15(3):531-47. doi: 10.3111/13696998.2012.662923. Epub 2012 Feb 21.

PMID:
22304338
9.

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.

Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, Conley RR.

Curr Med Res Opin. 2011 Apr;27(4):713-30. doi: 10.1185/03007995.2011.554533. Epub 2011 Jan 25. Review.

PMID:
21265593
10.

Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.

Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J.

J Med Econ. 2010;13(3):428-37. doi: 10.3111/13696998.2010.499758.

PMID:
20662625
11.

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, Culler SD.

Cost Eff Resour Alloc. 2009 Apr 7;7:4. doi: 10.1186/1478-7547-7-4.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk